Levetiracetam Solution
Product Images NDC 72162-2667

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72162-2667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemstructure (Chemstructure)

Chemical structure diagram of levetiracetam, illustrating its molecular framework including a pyrrolidone ring, an amide group, and an ethyl side chain attached to the central carbon.*

FDA Label Image

Image Description (Fig1)

An instructional formula diagram showing the calculation for total daily dose in mL per day. It divides the product of daily dose in mg per kg per day and patient weight in kg by the concentration of 100 mg/mL to determine the total daily dose volume.*

FDA Label Image

Fig2 (Fig2)

A text panel showing a formula for creatinine clearance calculation, incorporating age, weight, serum creatinine, and a gender adjustment factor for female patients.*

FDA Label Image

Fig3 (Fig3)

A formula illustrating the calculation of creatinine clearance per 1.73 square meters of body surface area (CLcr in mL/min/1.73m²), defined as creatinine clearance (CLcr in mL/min) divided by body surface area of the subject (BSA in m²), multiplied by 1.73.*

FDA Label Image

Fig4 (Fig4)

A bar chart showing the responder rate (≥ 50% reduction from baseline) in Study 1 for Levetiracetam oral solution at doses of 1000 mg/day and 3000 mg/day compared to placebo. The y-axis represents the percentage of patients, with placebo at 7.4%, Levetiracetam 1000 mg/day at 37.1%, and Levetiracetam 3000 mg/day at 39.6%. Bars for Levetiracetam doses are marked statistically significant versus placebo.*

FDA Label Image

Fig5 (Fig5)

A bar chart titled 'Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A' showing the percentage of patients responding to treatment. It compares placebo (6.3%), levetiracetam 1000 mg/day (20.8%), and levetiracetam 2000 mg/day (35.2%), with sample sizes indicated below each bar. Statistically significant differences versus placebo are marked with an asterisk.*

FDA Label Image

Fig6 (Fig6)

A bar chart showing responder rates defined as greater than 50% reduction from baseline in Study 3. The chart compares placebo (N=104) with a Levetiracetam oral solution dosage of 3000 mg/day (N=180), with responder rates of 14.4% and 39.4%, respectively. The Levetiracetam group shows a statistically significant higher responder rate compared to placebo.*

FDA Label Image

Fig7 (Fig7)

A bar graph titled 'Responder Rate (≥ 50% Reduction From Baseline) In Study 4' comparing percentage of patients responding to placebo versus levetiracetam. The y-axis shows percentage of patients from 0% to 45%. The placebo group (N=97) shows a responder rate of 19.6%, while the levetiracetam group (N=101) shows a higher responder rate of 44.6%, marked as statistically significant versus placebo.*

FDA Label Image

Fig8 (Fig8)

Bar chart showing responder rates (% of patients with ≥ 50% reduction from baseline) for patients aged 1 month to under 4 years in Study 5. It compares placebo (19.6%) and Levetiracetam treatment (43.1%), indicating a statistically significant higher response with Levetiracetam.*

FDA Label Image

Fig9 (Fig9)

Bar chart titled 'Responder Rate (≥ 50% Reduction From Baseline) In PGTC Seizure Frequency Per Week In Study 7' showing percentage of patients achieving this reduction. The chart compares placebo (45.2% response rate, N=84) versus levetiracetam (72.2% response rate, N=79), with a noted statistical significance for levetiracetam compared to placebo.*

FDA Label Image

Label (Lbl721622667)

Label for Levetiracetam Oral Solution USP 100 mg/mL by Bryant Ranch Prepack. The solution is contained in a 16 fl oz (473 mL) bottle. The label includes storage instructions, pharmacist dispensing guidelines, and a warning to keep out of reach of children. The product is Rx only and relabeled by Bryant Ranch Prepack, manufactured by Quagen Pharmaceuticals LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.